CN104833810A - Complement C3 detection method - Google Patents
Complement C3 detection method Download PDFInfo
- Publication number
- CN104833810A CN104833810A CN201510226757.7A CN201510226757A CN104833810A CN 104833810 A CN104833810 A CN 104833810A CN 201510226757 A CN201510226757 A CN 201510226757A CN 104833810 A CN104833810 A CN 104833810A
- Authority
- CN
- China
- Prior art keywords
- complement
- reagent
- latex
- detection method
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010028780 Complement C3 Proteins 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title claims abstract description 16
- 102000016918 Complement C3 Human genes 0.000 title claims abstract 13
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 45
- 239000004816 latex Substances 0.000 claims abstract description 14
- 229920000126 latex Polymers 0.000 claims abstract description 14
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 5
- 239000004793 Polystyrene Substances 0.000 claims abstract description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 5
- 229920002223 polystyrene Polymers 0.000 claims abstract description 5
- 238000004132 cross linking Methods 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims abstract description 4
- 238000004879 turbidimetry Methods 0.000 claims abstract description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims abstract 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract 3
- 238000010382 chemical cross-linking Methods 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims abstract 2
- 239000011780 sodium chloride Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 14
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims description 8
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 8
- 238000002835 absorbance Methods 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 238000001311 chemical methods and process Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 229920000151 polyglycol Polymers 0.000 claims description 2
- 239000010695 polyglycol Substances 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 1
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 1
- 239000012482 calibration solution Substances 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 6
- 241000283707 Capra Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 abstract 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 abstract 1
- 239000008055 phosphate buffer solution Substances 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 102100022133 Complement C3 Human genes 0.000 description 17
- 238000012360 testing method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a complement C3 detection method, which is based on the latex-enhanced immune turbidimetry. In the detection method, two liquid reagents (reagent R1 and reagent R2) are used, the reagent R1 comprises a phosphate buffer solution (pH=6), tween 20, disodium ethylene diamine tetraacetic acid (EDTA-2Na), sodium chloride, polyethylene glycol (PEG6000) and sodium azide; and the reagent R2 is a solution containing complement C3 latex particles. The detection method is characterized in that chemical crosslinking is used, and through the water-soluble carbodiimide (EDC) and N-hydroxy succinimide (NHS), the goat anti-human complement C3 antiserum can carry out covalent crosslinking with carboxylated polystyrene latex to form a complement C3 latex reagent. The complement C3 latex reagent has the advantages of high sensitivity, strong specificity, and simple preparation, and thus is worthy to promote and use.
Description
Technical field:
The invention belongs to biological technical field, a kind of Complement C_3 detection method is provided, has highly sensitive, high specificity, the simple feature of preparation of reagents, be worth further genralrlization to use.
Background technology:
C3 is the complement component that in serum, content is the highest, a kind of beta Globulin synthesized by macrophage, monocyte, lymphoid tissue, marrow, peritonaeum and liver etc., under the effect of C3 convertase, be cracked into C3a and C3b two fragments, all play a significant role in complement Classical pathway and alternative activation pathway.
C3 is the one that in each composition of complement, content is the highest, and is most important link in complement activation pathway, therefore the mensuration of its content is extremely important.C3 increases and substantially conforms to complement activity with minimizing, but more responsive.Acute glomerulonephritis, Lupus Nephritis Patients change of serum C 3 content of about 70%-80% reduce, and can recover normal, therefore the mensuration of C3 not only contribute to diagnosis after disease amelioration, can also observe the curative effect and monitoring prognosis.C3 reduction is also shown in autoimmune disease, respiratory distress syndrome of newborn, bacteremia, histologic lesion and chronic hepatitis.
The detection method of Complement C_3 has simple immunodiffusion method, ELISA method, Immunity transmission turbidity etc.Simple immunodiffusion method is time-consuming, and variation is large, and result is not easily observed, and measures diameter out of true; ELISA method repeatability is bad, easily occurs false positive, has the greatest impact by temperature and time; The first two method that Immunity transmission turbidity is better than relatively, but there is the large shortcoming of required antiserum amount.The present invention adopts latex enhancing immune turbidimetry, not only highly sensitive, and accuracy is good, not time-consuming advantage, and required sample size is few, saves more economically.
Summary of the invention:
The object of the invention is to, prepare Complement C_3 emulsion reagent in a large number, to improve Complement C_3 detection efficiency, strengthen detection accuracy.
Technical scheme of the present invention: applied chemistry method is cross-linked, make goat-anti human complement c 3 antiserum and Carboxylated Polystyrene latex covalent cross-linking by water-soluble carbodiimide (EDC) and N-hydroxy-succinamide (NHS), form Complement C_3 emulsion reagent.Concrete operations are as follows:
The preparation of Complement C_3 emulsion reagent:
To get particle diameter be 100nm concentration is 5% latex microsphere 1ml, add 100mmol/L, the phosphate buffer 9ml of PH6.0, mix rear 5mg water-soluble carbodiimide (EDC) and the N-hydroxy-succinamide (NHS) of adding respectively, stirring at room temperature 20min, 2-8 DEG C of centrifugal 30min (rotating speed 12000), with 100mmol/L, the phosphate buffer of PH6.0 washs three times, removing supernatant, get precipitation 100mmol/L, the phosphate buffer 1 ml of PH6.0 is resuspended, and add 200 μ l goat-anti human complement c 3 antiserums, stirring at room temperature 5h, 2-8 DEG C of centrifugal 30min (rotating speed 12000), precipitation is with containing 0.05% Tween-20 (Tween 20), 100mmol/L, the phosphate buffer of PH6.0 washs three times, removing supernatant, gained precipitation 100mmol/L, the phosphate buffer of PH6.0 dilutes, 2-8 DEG C of sealing is preserved.
This detection side ratio juris be by antibody linked for goat-anti human complement c 3 in present latex particulate, with the Complement C_3 generation antigen-antibody reaction in testing sample, cause microparticle agglutination, form certain turbidity, under 340nm wavelength, by the calibration object contrast processed equally, quantitatively detect the content of Complement C_3 in sample.
Accompanying drawing illustrates:
Fig. 1 adopts reagent of the present invention and commercial reagent A respectively, adopts Olympus 400 automatic clinical chemistry analyzer, to 50 increments this (comprising normal and exceptional sample), measures, and carry out correlation analysis to measured value by each autoregressive parameter.The measured value of what wherein X-axis represented is reagent of the present invention, the measured value of what Y-axis represented is commercial reagent A.Related coefficient: r
2=0.9948, linear equation is: y=1.041x-0.054.
Fig. 2: adopt Olympus 400 automatic clinical chemistry analyzer, the reagent of 5 gradient concentrations is measured, and correlation analysis is carried out to measured value.What wherein X-axis represented is dilute concentration, and what Y-axis represented is measured value average.Related coefficient: r
2=0.9963, linear equation is: y=1.0272x-0.0007.
Embodiment:
Embodiment
The inventive method is mixed with kit, carries out carrying out Performance comparision with commercial reagent box:
The concrete composition that reagent of the present invention is made into kit is as follows:
Complement C_3 detects the use of reagent:
1) detecting instrument: the Biochemical Analyzer with 340nm wavelength, 37 DEG C of thermostats.
2) sample to be tested: fresh not haemolysis serum, 2-8 DEG C of Absorbable organic halogens seven days.-20 DEG C of Absorbable organic halogens one month.
3) concrete trace routine:
4) result of calculation: Complement C_3 concentration (g/L)=Δ AT/ Δ AS × Cs
Δ AT: sample hose absorbance
Δ AS: calibration tube absorbance
Cs: calibration object concentration value
5) reference range: 0.9 ~ 1.5g/L
6) precision: CV≤4% in batch; Relative extreme difference≤6% between batch.
7) accuracy: relative deviation controls in ± 10%.
8) range of linearity: within the scope of 0.1 ~ 3g/L, correlation coefficient r >=0.990.
The commercially available import reagent A of contrast, its information is as follows:
Name of product: Complement C_3 detection kit (immunoturbidimetry)
Cleaning Principle: the C3 antibody in human serum in Complement C_3 and antiserum reagent forms antigen antibody complex, and make reactant liquor occur turbidity, the concentration recording Complement C_3 in serum is compared in the change detecting absorbance under 340nm with standard items.
Main composition:
Reagent R1:TRIS damping fluid: 100mmol/L, pH 8.0
Polyglycol: 3.0%
Antiseptic
Reagent R2: anti-human C3/C3b/C3c antibody (goat): according to titre
TRIS damping fluid: 33mmol/L
Antiseptic
Commercial reagent A by specification operation.
Example 1 reagent of the present invention compares with the performance index of commercial reagent A:
1) precision measures: in same sample, continuous drawing measures for 20 times, calculates the mean of measured value, standard deviation and the coefficient of variation,
Table 1 precision testing result
Coefficient of variation CV is generally used for the precision of a measurement assay method, and CV value is less, represents that the result precision of this assay method is better.For clinical chemistry test project, CV be less than 5% method precision generally acknowledge be acceptable.In table 1, the CV value of reagent of the present invention is less than commercial reagent A, shows that the precision of the inventive method is slightly better than commercial reagent A.
2) linear determination: adopt reagent of the present invention and commercial reagent A respectively, adopt Olympus 400 automatic clinical chemistry analyzer, to 50 increments this (comprising normal and exceptional sample), measure by each autoregressive parameter, and correlation analysis is carried out to measured value (the results are shown in Figure 1, what X-axis represented is the measured value that the present invention tries, the measured value of what Y-axis represented is commercial reagent A).Related coefficient: r
2=0.9948, linear equation is: y=1.041x-0.054, and result shows that this reagent and commercial reagent correlativity are good.
Table 2 linear correlation detection result
Example 2 preparation of reagents of the present invention becomes kit correlated performance to assess
1) precision measures: in same sample, continuous drawing measures for 20 times, calculates the mean of measured value, standard deviation and the coefficient of variation,
Table 3 precision testing result
Coefficient of variation CV is generally used for the precision of a measurement assay method, and CV value is less, represents that the result precision of this assay method is better.For clinical chemistry test project, CV be less than 5% method precision generally acknowledge be acceptable.In table 3, CV value is less than 3%, shows that the inventive method has excellent precision.
2) accuracy determination: use same quality-control product, replication 3 times, averages, should in ± 10% scope with quality-control product target value relative deviation.
Table 4 accuracy testing result
Relative deviation CB=-2.00% in table 4, be in ± 10% scope in, show that the inventive method has excellent accuracy.
3) linear determination: use deionized water reagent dilutions to be become 5 gradient concentrations, each gradient concentration detects 3 times, averages, and does regretional analysis to measured value and desired value, calculates r value and relative deviation (the results are shown in Figure 2, unit g/L).
Table 5 linear correlation detection result
Related coefficient is obtained: r by table 5
2=0.9963, linear equation is: y=1.0272x-0.0007, and result shows that this reagent correlativity is good.
4) Stability Determination: the present invention is detected reagent and be placed on room temperature and 4 DEG C of refrigerators respectively, substitute sample with freshly prepared 3.0g/L human complement c 3 standard items, measured 1 time every 1 month, and aggegation required time appears in record, the results are shown in Table 6.Result shows, kit is placed at 4 DEG C of refrigerators and do not had obvious loss of activity in more than at least 6 months, but should not deposit in room temperature.
Table 6 Detection of Stability result
| Under room temperature | There is the time (min) of aggegation | At 4 DEG C | There is the time (min) of aggegation |
| New preparation | 1 | New preparation | 1 |
| Deposit 1 month | 2 | Deposit 1 month | 1 |
| Deposit 2 months | Not aggegation | Deposit 2 months | 1 |
| Deposit 3 months | Not aggegation | Deposit 3 months | 1 |
| Deposit 4 months | Not aggegation | Deposit 4 months | 1 |
| Deposit 5 months | Not aggegation | Deposit 5 months | 1 |
| Deposit 6 months | Not aggegation | Deposit 6 months | 1 |
5) specific assay: choose 3 kinds of potential interference things and carry out interference experiment mensuration, equal unrestraint effect, show that this kit has good specificity, result is as shown in table 7:
Table 7 specific detection result
Claims (4)
1. the invention provides a kind of Complement C_3 detection method, described detection method is based on latex enhancing immune turbidimetry, for liquid double reagent, comprise reagent R1 and R2, described reagent R1 contains PH6.0 phosphate buffer, Tween-20 (Tween 20), disodium ethylene diamine tetraacetate (EDTA-2Na), sodium chloride, polyglycol (PEG6000), Sodium azide; Reagent R2 is the solution containing Complement C_3 latex particle, its feature is that applied chemistry method is cross-linked, make goat-anti human complement c 3 antiserum and Carboxylated Polystyrene latex covalent cross-linking by water-soluble carbodiimide (EDC) and N-hydroxy-succinamide (NHS), form Complement C_3 emulsion reagent.
2. Chemical Crosslinking Methods prepares Complement C_3 emulsion reagent according to claim 1, it is characterized in that Carboxylated Polystyrene latex particle size used is 100nm.
3. Chemical Crosslinking Methods prepares Complement C_3 emulsion reagent according to claim 1, it is characterized in that adding water-soluble carbodiimide (EDC) and N-hydroxy-succinamide (NHS) in Carboxylated Polystyrene latex and goat-anti people C3 antiserum covalent cross-linking process respectively.
4. according to claim 1, it is characterized in that the computing formula of mAlb in sample is:
Complement C_3 concentration (g/L)=Cs × Δ A in sample
t/ Δ A
s
In formula: Δ A
twith the sample hose absorbance of blank tube absorbance for contrast;
Δ A
swith the calibration tube absorbance of blank tube absorbance for contrast;
C
sthe concentration of Complement C_3 in calibration solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510226757.7A CN104833810A (en) | 2015-05-02 | 2015-05-02 | Complement C3 detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510226757.7A CN104833810A (en) | 2015-05-02 | 2015-05-02 | Complement C3 detection method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104833810A true CN104833810A (en) | 2015-08-12 |
Family
ID=53811822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510226757.7A Pending CN104833810A (en) | 2015-05-02 | 2015-05-02 | Complement C3 detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104833810A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106483299A (en) * | 2016-10-03 | 2017-03-08 | 王贤俊 | A kind of method for detecting superoxide dismutase content in human serum |
| CN107490676A (en) * | 2017-08-10 | 2017-12-19 | 迈克生物股份有限公司 | A kind of Complement C_3 detection kit and detection method |
| CN109752332A (en) * | 2017-11-07 | 2019-05-14 | 重庆中元汇吉生物技术有限公司 | A kind of C1Q detection kit |
| CN111693697A (en) * | 2020-07-07 | 2020-09-22 | 上海怡珏生物科技有限公司 | Application of C3C antibody in preparation of detection kit |
-
2015
- 2015-05-02 CN CN201510226757.7A patent/CN104833810A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106483299A (en) * | 2016-10-03 | 2017-03-08 | 王贤俊 | A kind of method for detecting superoxide dismutase content in human serum |
| CN107490676A (en) * | 2017-08-10 | 2017-12-19 | 迈克生物股份有限公司 | A kind of Complement C_3 detection kit and detection method |
| CN109752332A (en) * | 2017-11-07 | 2019-05-14 | 重庆中元汇吉生物技术有限公司 | A kind of C1Q detection kit |
| CN111693697A (en) * | 2020-07-07 | 2020-09-22 | 上海怡珏生物科技有限公司 | Application of C3C antibody in preparation of detection kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101769932B (en) | Full-range C-reactive protein detection kit | |
| Evans | Manual and automated methods for measuring urea based on a modification of its reaction with diacetyl monoxime and thiosemicarbazide. | |
| CN102253217B (en) | Detection kit of latex particle enhanced neutrophil gelatinase-associated lipid transfer protein | |
| CN102621332B (en) | Retinol binding protein assay kit based on latex particle coating | |
| CN102507918B (en) | Kit for determining anti-cyclic citrullinated peptide (Anti-CCP) antibody | |
| CN101699287B (en) | Homogeneous phase sol particle type cystatin C measuring kit and preparation method thereof | |
| CN103592445A (en) | Kit for detecting procalcitonin | |
| CN105510604A (en) | Method for improving sensitivity and linearity of latex reagent | |
| CN102393456B (en) | Kit for detecting Hepassocin (HPS) | |
| JP6749337B2 (en) | Prostate antigen standards and their use | |
| CN104849473A (en) | Microalbuminuria detection kit and preparation thereof | |
| CN110862881A (en) | Special cleaning solution or diluent for full-automatic chemiluminescence determinator and preparation method thereof | |
| CN104215770A (en) | Two-particle-based retinol binding protein detection kit | |
| CN104034893B (en) | A kind of melamine rapid detection method based on latex and kit | |
| CN104833810A (en) | Complement C3 detection method | |
| CN105203748A (en) | Full-range quantitative detection kit for C-reactive protein | |
| CN105277717A (en) | Magnetic particle separation chemiluminescence immunoassay method for thyroglobulin | |
| CN102243241A (en) | Homogeneous phase aerosol particle-type neutrophile granulocyte gelatinase-related lipid carrier protein determination kit and preparation method thereof | |
| CN105353139A (en) | Parathyroid hormone quantitative determination kit | |
| CN105929166A (en) | Magnetic particle-based quantitative chemiluminescent assay kit for anti-LKM-1 antibody IgG, and preparation and detection methods thereof | |
| CN107247138B (en) | It is a kind of for measuring the method for coating of the Chemiluminescent plate of d-dimer content | |
| CN105699665A (en) | Detection kit of lipocalin related to neutrophil gelatinase | |
| CN108663526B (en) | Secondary antibody competes immunoturbidimetry assay kit and its making and use method | |
| CN102866256A (en) | Detection method and detection reagent for hypersensitive C reactive protein | |
| CN104849224A (en) | Complement C3 detection kit and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150812 |